Exploiting Atropisomerism to Increase the Target Selectivity of Kinase Inhibitors
- 14 August 2015
- journal article
- Published by Wiley in Angewandte Chemie
- Vol. 127 (40) , 11920-11925
Abstract
No abstract availableKeywords
Funding Information
- SDSU startup
- SDSU University Grants Program
This publication has 39 references indexed in Scilit:
- Biological Stereoselectivity of Atropisomeric Natural Products and DrugsChirality, 2013
- Atropisomerism Observed in Indometacin DerivativesOrganic Letters, 2011
- Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging CorrelationClinical Cancer Research, 2010
- Discovery of a Novel Series of Semisynthetic Vancomycin Derivatives Effective against Vancomycin-Resistant BacteriaJournal of Medicinal Chemistry, 2010
- Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid CancerJournal of Clinical Oncology, 2010
- Measuring and interpreting the selectivity of protein kinase inhibitorsJournal of Chemical Biology, 2009
- Atropisomeric small molecule Bcl-2 ligands: Determination of bioactive conformationBioorganic & Medicinal Chemistry Letters, 2009
- The selectivity of protein kinase inhibitors: a further updateBiochemical Journal, 2007
- An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor ReceptorCell, 2006
- Atropselektive Synthese axial‐chiraler BiaryleAngewandte Chemie, 2005